The use and misuse of risk prediction tools for clinical decision-making.
作者信息
van Maaren Marissa C, Hueting Tom A, Völkel Vinzenz, van Hezewijk Marjan, Strobbe Luc Ja, Siesling Sabine
机构信息
Department of Health Technology and Services Research, Technical Medical Centre, University of Twente, Enschede, the Netherlands; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands.
Evidencio Medical Decision Support, Haaksbergen, the Netherlands.
出版信息
Breast. 2023 Jun;69:428-430. doi: 10.1016/j.breast.2023.01.006. Epub 2023 Jan 21.
Abstract
摘要
相似文献
1
The use and misuse of risk prediction tools for clinical decision-making.
Breast. 2023 Jun;69:428-430. doi: 10.1016/j.breast.2023.01.006. Epub 2023 Jan 21.
2
Pilot study of decision support tools on breast cancer chemoprevention for high-risk women and healthcare providers in the primary care setting.
BMC Med Inform Decis Mak. 2018 Dec 17;18(1):134. doi: 10.1186/s12911-018-0716-5.
3
Making the breast multidisciplinary team meeting relevant again.
Breast J. 2020 Sep;26(9):1915-1916. doi: 10.1111/tbj.13837. Epub 2020 Apr 11.
4
Key Elements of Mammography Shared Decision-Making: a Scoping Review of the Literature.
J Gen Intern Med. 2018 Oct;33(10):1805-1814. doi: 10.1007/s11606-018-4576-6. Epub 2018 Jul 20.
5
The availability and effectiveness of tools supporting shared decision making in metastatic breast cancer care: a review.
BMC Palliat Care. 2018 May 11;17(1):74. doi: 10.1186/s12904-018-0330-4.
6
Integrating clinicopathologic and genomic tools in chemotherapy decision-making for early stage breast cancer.
Future Oncol. 2017 Dec;13(28):2507-2510. doi: 10.2217/fon-2017-0452. Epub 2017 Nov 23.
7
Use of an Online Breast Cancer Risk Assessment and Patient Decision Aid in Primary Care Practices.
J Womens Health (Larchmt). 2020 Jun;29(6):763-769. doi: 10.1089/jwh.2019.8143. Epub 2020 Mar 10.
8
Communicating prognosis to women with early breast cancer - overview of prediction tools and the development and pilot testing of a decision aid.
BMC Health Serv Res. 2019 Mar 15;19(1):171. doi: 10.1186/s12913-019-3988-2.
9
The role of comorbidity assessment in guiding treatment decision-making for women with early breast cancer: a systematic literature review.
Support Care Cancer. 2020 Mar;28(3):1041-1050. doi: 10.1007/s00520-019-05218-w. Epub 2019 Dec 11.
10
When Is Using a Prediction Model Better Than No Model to Inform Clinical Decision Making?
J Urol. 2022 Sep;208(3):530-533. doi: 10.1097/JU.0000000000002833. Epub 2022 Jun 24.
引用本文的文献
1
Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, INFLUENCE 2.0, CTS5)?
Breast. 2025 Jul 4;83:104528. doi: 10.1016/j.breast.2025.104528.
2
Bridging the Gap: A Mixed-Methods Study on Factors Influencing Breast Cancer Clinicians' Decisions to Use Clinical Prediction Models.
MDM Policy Pract. 2025 Mar 27;10(1):23814683251328377. doi: 10.1177/23814683251328377. eCollection 2025 Jan-Jun.
3
Emergency department early mortality model for patients admitted after presenting to a tertiary medical center emergency department.
Acad Emerg Med. 2025 Jun;32(6):650-658. doi: 10.1111/acem.15096. Epub 2025 Jan 16.
4
The INFLUENCE 3.0 model: Updated predictions of locoregional recurrence and contralateral breast cancer, now also suitable for patients treated with neoadjuvant systemic therapy.
Breast. 2025 Feb;79:103829. doi: 10.1016/j.breast.2024.103829. Epub 2024 Oct 28.
5
Relationship between spinal alignment and functional disability after thoracolumbar spinal fractures: A systematic review.
N Am Spine Soc J. 2024 Jul 18;19:100529. doi: 10.1016/j.xnsj.2024.100529. eCollection 2024 Sep.
本文引用的文献
1
Development and validation of the PORTRET tool to predict recurrence, overall survival, and other-cause mortality in older patients with breast cancer in the Netherlands: a population-based study.
Lancet Healthy Longev. 2021 Nov;2(11):e704-e711. doi: 10.1016/S2666-7568(21)00229-4. Epub 2021 Nov 3.
2
Incorporating progesterone receptor expression into the PREDICT breast prognostic model.
Eur J Cancer. 2022 Sep;173:178-193. doi: 10.1016/j.ejca.2022.06.011. Epub 2022 Aug 4.
3
A scoping review of interactive and personalized web-based clinical tools to support treatment decision making in breast cancer.
Breast. 2022 Feb;61:43-57. doi: 10.1016/j.breast.2021.12.003. Epub 2021 Dec 6.
4
Improved risk estimation of locoregional recurrence, secondary contralateral tumors and distant metastases in early breast cancer: the INFLUENCE 2.0 model.
Breast Cancer Res Treat. 2021 Oct;189(3):817-826. doi: 10.1007/s10549-021-06335-z. Epub 2021 Aug 2.
5
TRIPOD Reporting Guidelines for Diagnostic and Prognostic Studies.
JAMA Surg. 2021 Jul 1;156(7):675-676. doi: 10.1001/jamasurg.2021.0537.
6
Assessing the impact of unmeasured confounders for credible and reliable real-world evidence.
Pharmacoepidemiol Drug Saf. 2020 Oct;29(10):1219-1227. doi: 10.1002/pds.5117. Epub 2020 Sep 14.
7
Prediction meets causal inference: the role of treatment in clinical prediction models.
Eur J Epidemiol. 2020 Jul;35(7):619-630. doi: 10.1007/s10654-020-00636-1. Epub 2020 May 22.
8
PROBAST: A Tool to Assess the Risk of Bias and Applicability of Prediction Model Studies.
Ann Intern Med. 2019 Jan 1;170(1):51-58. doi: 10.7326/M18-1376.
9
An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation.
Breast Cancer Res. 2017 May 22;19(1):58. doi: 10.1186/s13058-017-0852-3.
10
Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration.
Ann Intern Med. 2015 Jan 6;162(1):W1-73. doi: 10.7326/M14-0698.
Zotero 插件